Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
Actuate Therapeutics, Inc. Common stock
ACTU
Volume
865.99K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
ACTU
AC
Actuate Therapeutics, Inc. Common stock
ACTU
News
·
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
Mkt Cap
$12.0M
Volume
865.99K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.
Zacks Investment Research · Oct 8, 2026
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Actuate Therapeutics presented clinical data at ASCO 2026 showing that elraglusib combined with chemotherapy regimens (gemcitabine/Abraxane and FOLFIRINOX) demonstrated significant survival improvements in metastatic pancreatic cancer patients, particularly those with wild-type KRAS and TP53 genomics. The drug showed favorable tolerability across both combination settings, with median overall survival improvements ranging from 6-7 months in certain patient subgroups.
GlobeNewswire Inc. · Jun 1, 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Actuate Therapeutics announced that CEO Dan Schmitt will present at the Citizens Life Sciences Conference on March 10, 2026. The company also plans to expand its clinical pipeline by advancing elraglusib tablet into a Phase 1/2 clinical program for refractory cancers, with the phase 1 portion planned to initiate in the second half of 2026.
GlobeNewswire Inc. · Mar 4, 2026
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
Actuate Therapeutics successfully closed a $17.25 million public offering of 2,464,286 common stock shares at $7.00 per share, including the full exercise of an over-allotment option. The company plans to use the net proceeds of approximately $15.62 million for working capital and general corporate purposes.
Benzinga · Sep 11, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Actuate Therapeutics' Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival.
GlobeNewswire Inc. · May 31, 2025
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
Actuate Therapeutics, a clinical-stage biopharmaceutical company, will present data on its investigational drug elraglusib for the treatment of advanced salivary gland carcinoma at the AACR Annual Meeting 2025. The data suggests elraglusib in combination with chemotherapy and immunotherapy may be a promising approach for this rare and difficult-to-treat cancer type.
GlobeNewswire Inc. · Apr 17, 2025
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, and enable the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.
GlobeNewswire Inc. · Oct 29, 2024
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Actuate Therapeutics' elraglusib demonstrated anti-tumor activity with two ongoing complete responses and a 62% disease control rate in a Phase 1/2 trial for relapsed/refractory Ewing sarcoma. Enrollment is ongoing, with topline data anticipated in the first half of 2025.
GlobeNewswire Inc. · Sep 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AC
ACTU
Actuate Therapeutics, Inc. Common stock
Buy
Sell
Market
Limit
Soon
ACTU
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ACTU yet.
Related Tickers
Earnings